Regenerative medicine company Orthocell (ASX OCC) has marked another significant milestone in its global expansion, completing the first surgical case using its flagship nerve repair device, Remplir, in Hong Kong.
The launch coincided with the Hong Kong Orthopaedic Association’s (HKOA) 45th Annual Congress, where the technology was formally introduced to leading surgeons and clinical specialists.
The debut follows the appointment of MontsMed as Orthocell’s exclusive in-country distributor, a partnership that will drive access to key hospitals and orthopaedic specialists across Hong Kong. The city serves as a strategic entry point to the Guangdong–Hong Kong–Macao Greater Bay Area, which is home to approximately 100 million people and is positioned as one of Asia’s most advanced healthcare markets.
Chief Executive Officer and Managing Director Paul Anderson said the milestone represented a critical step in the company’s Asia-Pacific commercialisation strategy.
“The completion of our first Remplir surgical case and successful launch at the Hong Kong Orthopaedic Association Annual Congress represent important progress in our deliberate and considered approach to commercialising Remplir across Asia. Hong Kong’s advanced healthcare system and its role as a gateway to the Greater Bay Area present a compelling opportunity for expansion,” he said.
Orthocell continues to build momentum internationally, with Remplir now available in Australia, New Zealand, Singapore, the United States, and Hong Kong, and sales in Canada and Thailand expected soon. The company’s global strategy is led by newly appointed Commercial Director Hamish Thrum, who oversees distributor partnerships and market expansion across Asia.
Supported by over $50 million in cash and no debt, Orthocell is strongly positioned to accelerate its growth. The company expects a step change in revenue through the financial year 2026 as it scales product adoption across major markets, including the US$1.6 billion U.S. nerve repair market, where early hospital adoption and surgical case numbers continue to grow.